Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Paclitaxel
Drug: Epirubicin

First Posted Date: 2006-06-14

Last Posted Date: 2012-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 273

Registration Number: NCT00336791

Locations: 🇪🇸
Grupo Español de Investigacion en Cancer de Mama, Madrid, Spain
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇲🇽
Centro Medico Nacional de Occidente, Guadalajara, Mexico

and more 1 locations

Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

First Posted Date: 2006-06-08

Last Posted Date: 2012-07-10

Lead Sponsor: Northwestern University

Target Recruit Count: 32

Registration Number: NCT00334763

Locations: 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Evanston Northwestern Healthcare - Evanston Hospital, Evanston, Illinois, United States

and more 2 locations

Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel

First Posted Date: 2006-06-08

Last Posted Date: 2010-03-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 62

Registration Number: NCT00334802

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients

Phase 1

Completed

Conditions: Endometrial Cancer

Interventions: Radiation: IMRT
Radiation: Intracavitary vaginal brachytherapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-06-07

Last Posted Date: 2015-10-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 65

Registration Number: NCT00334321

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2

Terminated

Conditions: Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Procedure: cytoreductive surgery

First Posted Date: 2006-05-31

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 7

Registration Number: NCT00331422

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Phase 2

Completed

Conditions: Extraocular Extension Melanoma
Iris Melanoma
Recurrent Intraocular Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Metastatic Intraocular Melanoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: sorafenib tosylate

First Posted Date: 2006-05-25

Last Posted Date: 2014-07-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00329641

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: liposomal doxorubicin
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2006-05-16

Last Posted Date: 2023-03-27

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 820

Registration Number: NCT00326456

Locations: 🇵🇹
CHC Maternidade Bissaya-Barreto, Gynecology Unit, Coimbra, Portugal
🇮🇹
Ospedale di Bentivoglio, Bentivoglio, BO, Italy
🇮🇹
Azienda Ospedaliera S. Giuseppe Moscati, U.O. di Oncologia Medica, Monteforte Irpino, AV, Italy

and more 35 locations

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

Phase 2

Conditions: Stage III Pancreatic Cancer
Adenocarincoma of Pancreas
Stage IVB Pancreatic Cancer
Stage IVA Pancreatic Cancer

First Posted Date: 2006-05-09

Last Posted Date: 2007-05-08

Lead Sponsor: Seattle Cancer Treatment and Wellness Center

Target Recruit Count: 80

Registration Number: NCT00323583

Locations: 🇺🇸
Seattle Cancer Treatment and Wellness Center, Seattle, Washington, United States

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2006-05-08

Last Posted Date: 2013-11-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 1329

Registration Number: NCT00322452

Locations: 🇹🇭
Research Site, Songkla, Thailand

Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

Phase 2

Terminated

Conditions: Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Ovarian Cancer
Mixed Tumor, Mesodermal

Interventions: Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-05-08

Last Posted Date: 2018-09-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00322881

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy